OBJECTIVE: To develop longitudinal 3-dimensional (3-D) measures of outcomes of inflammation and bone erosion in murine arthritis using contrast-enhanced magnetic resonance imaging (CE-MRI) and in vivo microfocal computed tomography (micro-CT) and, in a pilot study, to determine the value of entry criteria based on age versus synovial volume in therapeutic intervention studies. METHODS: CE-MRI and in vivo micro-CT were performed on tumor necrosis factor-transgenic (TNF-Tg) mice and their wild-type littermates to quantify the synovial and popliteal lymph node volumes and the patella and talus bone volumes, respectively, which were validated histologically. These longitudinal outcome measures were used to assess the natural history of erosive inflammatory arthritis. We also performed anti-TNF versus placebo efficacy studies in TNF-Tg mice in which treatment was initiated according to either age (4-5 months) or synovial volume (3 mm(3) as detected by CE-MRI). Linear regression was performed to analyze the correlation between synovitis and focal erosion. RESULTS: CE-MRI demonstrated the highly variable nature of TNF-induced joint inflammation. Initiation of treatment by synovial volume produced significantly larger treatment effects on the synovial volume (P = 0.04) and the lymph node volume (P < 0.01) than did initiation by age. By correlating the MRI and micro-CT data, we were able to demonstrate a significant relationship between changes in synovial and patellar volumes (R(2) = 0.75, P < 0.01). CONCLUSION: In vivo CE-MRI and micro-CT 3-D outcome measures are powerful tools that accurately demonstrate the progression of erosive inflammatory arthritis in mice. These methods can be used to identify mice with arthritis of similar severity before intervention studies are initiated, thus minimizing heterogeneity in outcome studies of chronic arthritis seen between genetically identical littermates.
OBJECTIVE: To develop longitudinal 3-dimensional (3-D) measures of outcomes of inflammation and bone erosion in murinearthritis using contrast-enhanced magnetic resonance imaging (CE-MRI) and in vivo microfocal computed tomography (micro-CT) and, in a pilot study, to determine the value of entry criteria based on age versus synovial volume in therapeutic intervention studies. METHODS: CE-MRI and in vivo micro-CT were performed on tumor necrosis factor-transgenic (TNF-Tg) mice and their wild-type littermates to quantify the synovial and popliteal lymph node volumes and the patella and talus bone volumes, respectively, which were validated histologically. These longitudinal outcome measures were used to assess the natural history of erosive inflammatory arthritis. We also performed anti-TNF versus placebo efficacy studies in TNF-Tg mice in which treatment was initiated according to either age (4-5 months) or synovial volume (3 mm(3) as detected by CE-MRI). Linear regression was performed to analyze the correlation between synovitis and focal erosion. RESULTS: CE-MRI demonstrated the highly variable nature of TNF-induced joint inflammation. Initiation of treatment by synovial volume produced significantly larger treatment effects on the synovial volume (P = 0.04) and the lymph node volume (P < 0.01) than did initiation by age. By correlating the MRI and micro-CT data, we were able to demonstrate a significant relationship between changes in synovial and patellar volumes (R(2) = 0.75, P < 0.01). CONCLUSION: In vivo CE-MRI and micro-CT 3-D outcome measures are powerful tools that accurately demonstrate the progression of erosive inflammatory arthritis in mice. These methods can be used to identify mice with arthritis of similar severity before intervention studies are initiated, thus minimizing heterogeneity in outcome studies of chronic arthritis seen between genetically identical littermates.
Authors: B J Dardzinski; V J Schmithorst; S K Holland; G P Boivin; T Imagawa; S Watanabe; J M Lewis; R Hirsch Journal: Magn Reson Imaging Date: 2001-11 Impact factor: 2.546
Authors: Y Y Kong; U Feige; I Sarosi; B Bolon; A Tafuri; S Morony; C Capparelli; J Li; R Elliott; S McCabe; T Wong; G Campagnuolo; E Moran; E R Bogoch; G Van; L T Nguyen; P S Ohashi; D L Lacey; E Fish; W J Boyle; J M Penninger Journal: Nature Date: 1999-11-18 Impact factor: 49.962
Authors: A R Pettit; H Ji; D von Stechow; R Müller; S R Goldring; Y Choi; C Benoist; E M Gravallese Journal: Am J Pathol Date: 2001-11 Impact factor: 4.307
Authors: Kurt Redlich; Silvia Hayer; Andrea Maier; Colin R Dunstan; Makiyeh Tohidast-Akrad; Susanne Lang; Birgit Türk; Peter Pietschmann; Wolfgang Woloszczuk; Silva Haralambous; George Kollias; Günter Steiner; Josef S Smolen; Georg Schett Journal: Arthritis Rheum Date: 2002-03
Authors: Mikkel Østergaard; Charles Peterfy; Philip Conaghan; Fiona McQueen; Paul Bird; Bo Ejbjerg; Ron Shnier; Philip O'Connor; Mette Klarlund; Paul Emery; Harry Genant; Marissa Lassere; John Edmonds Journal: J Rheumatol Date: 2003-06 Impact factor: 4.666
Authors: David J Shealy; Paul H Wooley; Eva Emmell; Amy Volk; Amy Rosenberg; George Treacy; Carrie L Wagner; Lois Mayton; Don E Griswold; Xiao-Yu R Song Journal: Arthritis Res Date: 2002-06-28
Authors: Richard D Bell; Emily K Wu; Christopher A Rudmann; Megan Forney; Claire R W Kaiser; Ronald W Wood; Joe V Chakkalakal; Nicole D Paris; Alanna Klose; Guang-Qian Xiao; Javier Rangel-Moreno; Maria L Garcia-Hernandez; Christopher T Ritchlin; Edward M Schwarz; Homaira Rahimi Journal: Arthritis Rheumatol Date: 2019-07-22 Impact factor: 10.995
Authors: Safiehkhatoon Moshkani; Igor I Kuzin; Funmilola Adewale; Johan Jansson; Iñaki Sanz; Edward M Schwarz; Andrea Bottaro Journal: J Immunol Date: 2012-05-16 Impact factor: 5.422
Authors: Jie Li; Igor Kuzin; Safiehkhatoon Moshkani; Steven T Proulx; Lianping Xing; Denise Skrombolas; Robert Dunn; Iñaki Sanz; Edward M Schwarz; Andrea Bottaro Journal: J Immunol Date: 2010-04-30 Impact factor: 5.422
Authors: A Mitra; S Kundu-Raychaudhuri; C Abria; A Rona; A J Chaudhari; S P Raychaudhuri Journal: Clin Exp Immunol Date: 2017-02-24 Impact factor: 4.330
Authors: Echoe M Bouta; Richard D Bell; Homaira Rahimi; Lianping Xing; Ronald W Wood; Clifton O Bingham; Christopher T Ritchlin; Edward M Schwarz Journal: Nat Rev Rheumatol Date: 2018-01-11 Impact factor: 20.543
Authors: Edward M Schwarz; Steven T Proulx; Christopher T Ritchlin; Brendan F Boyce; Lianping Xing Journal: Adv Exp Med Biol Date: 2010 Impact factor: 2.622
Authors: Ruolin Guo; Quan Zhou; Steven T Proulx; Ronald Wood; Rui-Cheng Ji; Christopher T Ritchlin; Bronislaw Pytowski; Zhenping Zhu; Yong-Jun Wang; Edward M Schwarz; Lianping Xing Journal: Arthritis Rheum Date: 2009-09
Authors: Yawen Ju; Jie Li; Chao Xie; Christopher T Ritchlin; Lianping Xing; Matthew J Hilton; Edward M Schwarz Journal: Genesis Date: 2013-07-09 Impact factor: 2.487
Authors: Echoe M Bouta; Ronald W Wood; Edward B Brown; Homaira Rahimi; Christopher T Ritchlin; Edward M Schwarz Journal: J Physiol Date: 2014-01-13 Impact factor: 5.182